Dexamethasone [700 mcg intravitreal implant] for use as an alternative treatment for Diabetic Macular Edema (DME) and as an alternative treatment for Macular Edema secondary to Retinal Vein Occlusion (ME-RVO) among those contraindicated or non-responsive to first-line anti-VEGF drugs
Pre-Cycle 1 | DrugsHTA Council Recommendation (as of 18 February 2026)
As a final recommendation, the HTA Council recommends the government financing of dexamethasone [700 mcg intravitreal implant] as an alternative treatment for Diabetic Macular Edema (DME) and Macular Edema secondary to Retinal Vein Occlusion (ME-RVO) for patients contraindicated or non-responsive to anti-vascular endothelial growth factor (VEGF) drugs.
Relevant Information
- Status: With Final HTA Council Recommendation and SOH Decision
- Topic Assignment: Internal Assessment
- Policy Question: Should dexamethasone [700 mcg intravitreal implant] as an alternative treatment for Diabetic Macular Edema (DME) and Macular Edema secondary to Retinal Vein Occlusion (ME-RVO) for patients contraindicated or non-responsive to anti-vascular endothelial growth factor (VEGF) drugs be funded by the government?
- Secretary of Health Decision: Approved as of 06 May 2026
Evidence and Relevant Documents